Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Gastrointestinal 3CNS 2Breast 2Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Lymphoma 539Precursor Cell Lymphoblastic Leukemia-Lymphoma 499Lymphoma, Non-Hodgkin 435Lymphoma, Follicular 403Leukemia, Lymphocytic, Chronic, B-Cell 388Lymphoma, Large B-Cell, Diffuse 385Lymphoma, B-Cell 246Lymphoma, Mantle-Cell 222Hodgkin Disease 207Recurrence 204Leukemia, Myeloid, Acute 197Leukemia 191Multiple Myeloma 184Burkitt Lymphoma 181Lymphoma, B-Cell, Marginal Zone 170Neoplasms 151Myelodysplastic Syndromes 132Hematologic Neoplasms 115Waldenstrom Macroglobulinemia 103Lymphoma, T-Cell, Peripheral 85Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 81Lymphoma, T-Cell 81Lymphoma, T-Cell, Cutaneous 66Leukemia, Myelogenous, Chronic, BCR-ABL Positive 62Mycosis Fungoides 57Leukemia, Biphenotypic, Acute 54Breast Neoplasms 54Myeloproliferative Disorders 50Leukemia, B-Cell 50Lymphoproliferative Disorders 47

Interventions

fludarabine phosphate 1fludarabine 1axicabtagene ciloleucel 1Simvastatin 1Interleukin 1 Receptor Antagonist Protein 1Dexamethasone 1Cyclophosphamide 1Bendamustine Hydrochloride 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neurotoxicity Syndromes × Lymphoid × 1 year × Clear all
NCT04514029 2026-01-08

Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel

Masonic Cancer Center, University of Minnesota

Phase EARLY_PHASE1 Active not recruiting
37 enrolled
Lymphoid

Lymphoma, Neurotoxicity Syndromes

NCT03696784 2025-12-08

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

UNC Lineberger Comprehensive Cancer Center

Phase 1 Active not recruiting
19 enrolled
Lymphoid

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, B-Cell, Neurotoxicity Syndromes

NCT04150913 2025-11-25

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Massachusetts General Hospital

Phase 2 Completed
15 enrolled 17 charts
Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡